Krabbe Disease Clinical Trial
— RESKUEOfficial title:
A Phase 1/2 Clinical Study of Intravenous Gene Transfer With an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE)
Verified date | June 2024 |
Source | Forge Biologics, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a nonblinded, non-randomized dose escalation study of intravenous AAVrh10 after hematopoietic stem cell transplantation (HSCT) in which subjects will receive standard of care hematopoietic cell transplantation for Krabbe disease, followed by a single infusion of an adeno-associated virus gene therapy product. Extensive natural history subjects will be used to compare as control group.
Status | Active, not recruiting |
Enrollment | 6 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Day to 12 Months |
Eligibility | Inclusion Criteria: 1. Diagnosis of infantile Krabbe disease, characterized by the following criteria outlined below: - Galactocerebrosidase (GALC) activity levels in leukocytes compatible with the diagnosis of Krabbe disease; AND AT LEAST ONE OF THE FOLLOWING: - Elevated psychosine levels predictive of infantile disease onset by DBS; OR - Imaging or neurophysiological findings consistent with Krabbe disease (CSF, MRI, NCV, ABR); OR - Two GALC mutations predictive to result in infantile onset phenotype. 2. Age at the time of screening: 1 day to 12 months 3. Participant has been deemed eligible for treatment with HSCT (standard of care) and a fully myeloablative reduced intensity/toxicity conditioning regimen (RIC/RTC) is/has been used 4. Participant's parents or legal guardian consents to participate in the study and provides informed consent according to IRB guidelines prior to any study procedures being performed 5. Parent(s) and/or legal guardian able to comply with the clinical protocol 6. Participant must have adequate organ function at time of screening as measured by: - Creatinine = 1.5x upper limit of age appropriate normal and creatinine clearance = 60 mL/min/1.73 m2 - Hepatic transaminases (ALT/AST) = 2x age related upper limit of normal - Ejection fraction of > 50% by echocardiogram or other appropriate study without evidence of pulmonary hypertension - Pulmonary evaluation testing demonstrating resting pulse oximeter > 95% on room air - Coagulation tests within 110% of normal ranges for age. (PT/INR and PTT) Exclusion Criteria: 1. History of prior treatment with a gene therapy product 2. Presence of major congenital anomaly or any other condition that affects neurodevelopmental function 3. Presence of any neurocognitive deficit or brain damage not attributable to Krabbe disease 4. Active aspiration 5. Signs of active infection or disease from cytomegalovirus, adenovirus or other viruses 6. HIV positive 7. Uncontrolled and progressive bacterial or fungal infection 8. Presence of any contraindication for MRI 9. Use of any investigational product prior to study enrollment or current enrollment in another study that involves clinical interventions 10. Any other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the PI, would preclude participation in the study 11. Ongoing veno-occlusive disease (VOD) as determined by liver ultrasound (moderate ascites and static or retrograde portal vein flow) the day before FBX-101 infusion. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan Hospitals - Michigan Medicine | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
Forge Biologics, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety as assessed by incidence and severity of adverse events and serious adverse events that are attributed to FBX-101. | 24 months | ||
Primary | Safety as assessed by HSCT incident of engraftment. | 24 months | ||
Secondary | Efficacy as assessed by improvement of probability to achieve independent sitting compared to untreated patients or those receiving HSCT only. | 12 months and 24 months | ||
Secondary | Efficacy as assessed by improvement of gross motor function as measured by Peabody Developmental Motor Scale 2nd Edition (PDMS-2) above a functional age equivalent of 12 months compared to untreated patients or those receiving HSCT only | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02993796 -
Krabbe Disease Global Patient Registry
|
||
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Terminated |
NCT00668564 -
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
|
Phase 2 | |
Not yet recruiting |
NCT06308718 -
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
|
||
Active, not recruiting |
NCT02699190 -
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
|
||
Completed |
NCT01938014 -
Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children
|
||
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Recruiting |
NCT05739643 -
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
|
Phase 1/Phase 2 | |
Recruiting |
NCT03047369 -
The Myelin Disorders Biorepository Project
|
||
Completed |
NCT01043640 -
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
|
Phase 2 | |
Withdrawn |
NCT01425489 -
Biomarker for Krabbe Disease (BioKrabbe)
|
||
Active, not recruiting |
NCT00787865 -
Diffusion Tensor Imaging (DTI) in Infants With Krabbe Disease
|